Moreover, the Gli1 inhibitor GANT61 exhibits synergistic effects with anti-PDL1 therapy, further highlighting the potential therapeutic value of the Hh pathway in HCC treatment [106]. The gene discussed is CD274; the disease is hepatocellular carcinoma.